Literature DB >> 25267895

Antipsychotic combinations for schizophrenia.

Nicola Maayan1, Karla Soares-Weiser1, Jun Xia2, Clive E Adams2.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objectives of this review are to examine whether: Treatment with antipsychotic combinations is effective for schizophrenia; andTreatment with antipsychotic combinations is safe for the same illness.

Entities:  

Year:  2011        PMID： 25267895      PMCID： PMC4176662          DOI： 10.1002/14651858.CD009005

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


  36 in total

1.  Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

Authors:  M C Gulliford; O C Ukoumunne; S Chinn
Journal:  Am J Epidemiol       Date:  1999-05-01       Impact factor: 4.897

2.  Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.

Authors:  R M Procyshyn; N B Kennedy; G Tse; B Thompson
Journal:  Can J Psychiatry       Date:  2001-05       Impact factor: 4.356

3.  Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.

Authors:  Nancy H Covell; Carlos T Jackson; Arthur C Evans; Susan M Essock
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

4.  What does the PANSS mean?

Authors:  Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R Engel
Journal:  Schizophr Res       Date:  2005-06-27       Impact factor: 4.939

Review 5.  When symptoms persist: choosing among alternative somatic treatments for schizophrenia.

Authors:  G W Christison; D G Kirch; R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

Review 6.  Statistics notes. Trials randomised in clusters.

Authors:  J M Bland; S M Kerry
Journal:  BMJ       Date:  1997-09-06

Review 7.  The clinical research base for the treatment of schizophrenia.

Authors:  N R Schooler; S J Keith
Journal:  Psychopharmacol Bull       Date:  1993

8.  [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

Authors:  J P Boissel; M Cucherat; W Li; G Chatellier; F Gueyffier; M Buyse; F Boutitie; P Nony; M Haugh; G Mignot
Journal:  Therapie       Date:  1999 Jul Aug       Impact factor: 2.070

9.  Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors.

Authors:  D L Leslie; R A Rosenheck
Journal:  Med Care       Date:  2001-09       Impact factor: 2.983

10.  The unit of analysis error in studies about physicians' patient care behavior.

Authors:  G W Divine; J T Brown; L M Frazier
Journal:  J Gen Intern Med       Date:  1992 Nov-Dec       Impact factor: 5.128
View more
  3 in total

Review 1.  Antipsychotic combinations for schizophrenia.

Authors:  Javier Ortiz-Orendain; Santiago Castiello-de Obeso; Luis Enrique Colunga-Lozano; Yue Hu; Nicola Maayan; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

Review 2.  Aripiprazole versus other atypical antipsychotics for schizophrenia.

Authors:  Priya Khanna; Tao Suo; Katja Komossa; Huaixing Ma; Christine Rummel-Kluge; Hany George El-Sayeh; Stefan Leucht; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2014-01-02

Review 3.  Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.

Authors:  Sharea Ijaz; Blanca Bolea; Simon Davies; Jelena Savović; Alison Richards; Sarah Sullivan; Paul Moran
Journal:  BMC Psychiatry       Date:  2018-09-03       Impact factor: 3.630
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.